Regulatory approval

Published by the Health Canada.

Health Canada approved blinatumomab for the treatment of patients with Philadelphia chromosome-negative CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.

This is written in the approval document as:

BLINCYTO (blinatumomab for injection) is indicated for the treatment of patients with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.

Citation

Amgen Canada Inc. Blincyto (blinatumomab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078156.PDF. Revised December 2024. Accessed June 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type Biomarker(s) Cancer type Therapy(ies)